Please login to the form below

Not currently logged in
Email:
Password:

PARP inihibitor

This page shows the latest PARP inihibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Meanwhile, Pfizer’s drug will also have to compete with two

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics